Literature DB >> 2526616

Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet.

R Koshida1, L Vrang, G Gilljam, J Harmenberg, B Oberg, B Wahren.   

Abstract

We describe a synergistic effect of combinations of foscarnet and 3'-azido-3'-deoxythymidine against human immunodeficiency virus type 1 multiplication in cell culture, an additive effect of foscarnet and 3'-azido-3'-deoxythymidine triphosphate against human immunodeficiency virus type 1 reverse transcriptase, and a low toxicity in cell culture of combinations of the two drugs.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2526616      PMCID： PMC172534          DOI： 10.1128/AAC.33.5.778

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  Inhibition of HTLV-III/LAV replication by foscarnet.

Authors:  P S Sarin; Y Taguchi; D Sun; A Thornton; R C Gallo; B Oberg
Journal:  Biochem Pharmacol       Date:  1985-11-15       Impact factor: 5.858

2.  Foscarnet for cytomegalovirus retinitis.

Authors:  D R Singer; T J Fallon; W E Schulenburg; G Williams; J Cohen
Journal:  Ann Intern Med       Date:  1985-12       Impact factor: 25.391

3.  Declining levels of HIV P24 antigen in serum during treatment with foscarnet.

Authors:  S Bergdahl; A Sönnerborg; A Larsson; O Strannegard
Journal:  Lancet       Date:  1988-05-07       Impact factor: 79.321

4.  Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate.

Authors:  E G Sandstrom; J C Kaplan; R E Byington; M S Hirsch
Journal:  Lancet       Date:  1985-06-29       Impact factor: 79.321

5.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

6.  Combined antiviral effect of interferon and acyclovir on herpes simplex virus types 1 and 2.

Authors:  T L Stanwick; R F Schinazi; D E Campbell; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

7.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

8.  Combined antiviral effects of interferon, adenine, arabinoside, hypoxanthine arabinoside, and adenine arabinoside-5'-monophosphate in human fibroblast cultures.

Authors:  Y J Bryson; L H Kronenberg
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

9.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728
View more
  16 in total

1.  Effectiveness of rescue antiretroviral therapy including intravenously administered zidovudine and foscarnet in a child with HIV-1 enteropathy.

Authors:  Marc Hainaut; Michèle Gérard; Cécile Alexandra Peltier; Hichem Souayah; Françoise Mascart; Georges Zissis; Jack Levy
Journal:  Eur J Pediatr       Date:  2003-05-09       Impact factor: 3.183

Review 2.  Antiretroviral therapy: reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

Review 3.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

Review 4.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

5.  Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine.

Authors:  X B Kong; Q Y Zhu; R M Ruprecht; K A Watanabe; J M Zeidler; J W Gold; B Polsky; D Armstrong; T C Chou
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

6.  Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.

Authors:  S Palmer; J Harmenberg; S Cox
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 7.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

8.  Conformational States of HIV-1 Reverse Transcriptase for Nucleotide Incorporation vs Pyrophosphorolysis-Binding of Foscarnet.

Authors:  Kalyan Das; Jan Balzarini; Matthew T Miller; Anita R Maguire; Jeffrey J DeStefano; Eddy Arnold
Journal:  ACS Chem Biol       Date:  2016-06-06       Impact factor: 5.100

9.  Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis.

Authors:  U R Hengge; N H Brockmeyer; R Malessa; U Ravens; M Goos
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

10.  Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Peter R Meyer; Suzanne E Matsuura; Dianna Zonarich; Rahul R Chopra; Eric Pendarvis; Holly Z Bazmi; John W Mellors; Walter A Scott
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.